/
Neurology
Peripheral Neuropathy
36
Pipeline Programs↗
88
Active Trials↗
45
Companies Involved↗
Peripheral Neuropathy is a moderately active landscape with 36 programs across 45 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Tarian Pharma, Vertex Pharmaceuticals. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 15
Phase 211
Phase 38
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
32 of 34 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 94% of 36 pipeline programs.
Analysis
Trial Status
282
clinical trials
Completed127 · 45%
Recruiting43 · 15%
Unknown status36 · 13%
Not yet recruiting26 · 9%
Terminated24 · 9%
Active, not recruiting18 · 6%
Other8 · 3%
Clinical Trials
Trial Activity
282 trials
Page 1 of 19
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)